558 related articles for article (PubMed ID: 17461853)
1. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.
Martínez E; Milinkovic A; Buira E; de Lazzari E; León A; Larrousse M; Loncá M; Laguno M; Blanco JL; Mallolas J; García F; Miró JM; Gatell JM
HIV Med; 2007 May; 8(4):251-8. PubMed ID: 17461853
[TBL] [Abstract][Full Text] [Related]
2. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
Bonnet F; Lewden C; May T; Heripret L; Jougla E; Bevilacqua S; Costagliola D; Salmon D; Chêne G; Morlat P
Cancer; 2004 Jul; 101(2):317-24. PubMed ID: 15241829
[TBL] [Abstract][Full Text] [Related]
3. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
[TBL] [Abstract][Full Text] [Related]
4. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.
Etard JF; Ndiaye I; Thierry-Mieg M; Guèye NF; Guèye PM; Lanièce I; Dieng AB; Diouf A; Laurent C; Mboup S; Sow PS; Delaporte E
AIDS; 2006 May; 20(8):1181-9. PubMed ID: 16691070
[TBL] [Abstract][Full Text] [Related]
5. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy.
Macías J; Melguizo I; Fernández-Rivera FJ; García-García A; Mira JA; Ramos AJ; Rivera JM; Pineda JA
Eur J Clin Microbiol Infect Dis; 2002 Nov; 21(11):775-81. PubMed ID: 12461586
[TBL] [Abstract][Full Text] [Related]
6. HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general population.
Ormaasen V; Sandvik L; Dudman SG; Bruun JN
Scand J Infect Dis; 2007; 39(1):51-7. PubMed ID: 17366013
[TBL] [Abstract][Full Text] [Related]
7. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
[TBL] [Abstract][Full Text] [Related]
8. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
Ives NJ; Gazzard BG; Easterbrook PJ
J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
[TBL] [Abstract][Full Text] [Related]
9. Effect of education on overall and cause-specific mortality in injecting drug users, according to HIV and introduction of HAART.
Jarrin I; Lumbreras B; Ferreros I; Pérez-Hoyos S; Hurtado I; Hernández-Aguado I
Int J Epidemiol; 2007 Feb; 36(1):187-94. PubMed ID: 17085455
[TBL] [Abstract][Full Text] [Related]
10. The shifting pattern of cause-specific mortality in a cohort of human immunodeficiency virus-infected and non-infected injecting drug users.
Ferreros I; Lumbreras B; Hurtado I; Pérez-Hoyos S; Hernández-Aguado I
Addiction; 2008 Apr; 103(4):651-9. PubMed ID: 18339110
[TBL] [Abstract][Full Text] [Related]
11. Progression of HIV infection in the post-HAART era among a cohort of HIV+ Greek haemophilia patients.
Katsarou O; Touloumi G; Antoniou A; Kouramba A; Hatzakis A; Karafoulidou A
Haemophilia; 2005 Jul; 11(4):360-5. PubMed ID: 16011588
[TBL] [Abstract][Full Text] [Related]
12. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
[TBL] [Abstract][Full Text] [Related]
13. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients.
Herida M; Mary-Krause M; Kaphan R; Cadranel J; Poizot-Martin I; Rabaud C; Plaisance N; Tissot-Dupont H; Boue F; Lang JM; Costagliola D
J Clin Oncol; 2003 Sep; 21(18):3447-53. PubMed ID: 12972519
[TBL] [Abstract][Full Text] [Related]
14. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
Omland LH; Weis N; Skinhøj P; Laursen A; Christensen PB; Nielsen HI; Møller A; Engsig F; Sørensen HT; Obel N
HIV Med; 2008 May; 9(5):300-6. PubMed ID: 18400077
[TBL] [Abstract][Full Text] [Related]
15. Evolution of the incidence and aetiology of fever of unknown origin (FUO), and survival in HIV-infected patients after HAART (Highly Active Antiretroviral Therapy).
Abellán-Martínez J; Guerra-Vales JM; Fernández-Cotarelo MJ; González-Alegre MT
Eur J Intern Med; 2009 Sep; 20(5):474-7. PubMed ID: 19712847
[TBL] [Abstract][Full Text] [Related]
16. Opportunistic infections and organ-specific diseases in HIV-1-infected children: a cohort study (1990-2006).
Guillén S; García San Miguel L; Resino S; Bellón JM; González I; Jiménez de Ory S; Muñoz-Fernández MA; Navarro ML; Gurbindo MD; de José MI; Mellado MJ; Martín-Fontelos P; Gonzalez-Tomé MI; Martinez J; Beceiro J; Roa MA; Ramos JT;
HIV Med; 2010 Apr; 11(4):245-52. PubMed ID: 20050937
[TBL] [Abstract][Full Text] [Related]
17. Trends in perimortal conditions and mortality rates among HIV-infected patients.
Hooshyar D; Hanson DL; Wolfe M; Selik RM; Buskin SE; McNaghten AD
AIDS; 2007 Oct; 21(15):2093-100. PubMed ID: 17885300
[TBL] [Abstract][Full Text] [Related]
18. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
[TBL] [Abstract][Full Text] [Related]
19. Reduction in liver-related hospital admissions and deaths in HIV-infected patients since the year 2002.
Martín-Carbonero L; Sánchez-Somolinos M; García-Samaniego J; Núñez MJ; Valencia ME; González-Lahoz J; Soriano V
J Viral Hepat; 2006 Dec; 13(12):851-7. PubMed ID: 17109686
[TBL] [Abstract][Full Text] [Related]
20. The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta.
Gingues S; Gill MJ
HIV Med; 2006 Sep; 7(6):369-77. PubMed ID: 16903981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
